Clin2
NCT07416123Worth exploringRecruiting

Study of a new drug for advanced solid tumors

Solid TumorsUrothelial Carcinoma

Part of Cancer clinical trials.

This trial tests an experimental drug, GEN1106, for people with solid tumors that have not responded to standard treatments. It aims to see if the drug can help shrink or control the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
103 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Your cancer must have progressed or not responded to all standard treatments (including chemo, immunotherapy, or targeted therapy).
  • You need to have at least one measurable tumor, meaning it can be seen on scans and measured.
  • You should be able to care for yourself and be up and about (a performance status of 0 or 1).
  • For the first part of the study, any solid tumor type is allowed. For later parts, you must have metastatic bladder cancer.
  • You cannot have received a type of drug called a topoisomerase 1 inhibitor-based antibody-drug conjugate before.
  • You need to be at least 4 weeks past any previous cancer treatment or 5 drug half-lives, whichever is shorter.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07090499Recruiting· Phase 1
Study of PF-08046876 for advanced solid tumors

This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.

Duarte, California
NCT05965856Recruiting· Phase 2
Testing two antibody medicines for advanced bladder and other cancers

This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.

Shanghai, Shanghai Municipality
NCT06953089Recruiting· Phase 2
Combination therapy study for advanced solid tumors

This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.

Los Angeles, California
NCT07387068Recruiting· Phase 1
Testing GEN1079 for advanced solid tumors

This trial tests an experimental drug called GEN1079 for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if it's safe and if it helps shrink tumors.

New Haven, Connecticut
NCT07695831Not yet recruiting· Phase 1
Testing a new drug (GEN1119) for solid tumors

This trial tests a new experimental drug called GEN1119 for people with solid tumors that have stopped responding to standard treatments. It's an early-phase study to see if the drug is safe and how well it works.

NCT07053904Enrolling by invitation· Phase 1
Study of two experimental cancer drugs for advanced solid tumors

This trial tests two new drugs, P1101 and P1801, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.

New Taipei City

Hear when a new Urothelial Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.